-
Mashup Score: 2
Here, we summarize a meta-analysis by Soltantabar et al. published in Clinical Pharmacology and Therapeutics on the impact of treatment modality and the route of administration of immunotherapies on the incidence of CRS in RRMM.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 20Teclistamab: real-world safety and efficacy - 2 day(s) ago
Here, we summarize a retrospective analysis presented by Dima at the 65th American Society of Hematology Annual Meeting and Exposition evaluating the safety and efficacy of teclistamab in the real-world setting.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8Dual antigen targeting immunotherapies in MM - 4 day(s) ago
Here we summarize a presentation by Sham Mailankody from the International Myeloma Society’s 5th Immune Effector Cell Therapies in Multiple Myeloma Workshop, 2024, on the dual antigen-targeting CAR T cells and trispecific antibodies in MM.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 12
During the International Myeloma Society 5th Immune Effector Cell Workshop, the Multiple Myeloma Hub was pleased to speak to Irene Ghobrial, Dana-Farber Cancer Institute, Boston, US. We asked, What is the rationale for T-cell therapies in the treatment of smoldering MM?
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 12
On April 22, 2024, the EC granted approval to cilta-cel for the treatment of RRMM after one or more prior therapies, including an IMiD or PI, who are lenalidomide-refractory with disease progression on the last therapy.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet-
🚨 NEWS 🚨 @EU_Commission approves cilta-cel for the treatment of relapsed/refractory #MultipleMyeloma after ≥1 prior therapy, including an IMiD or PI, who are lenalidomide-refractory with disease progression on the last therapy. Read more: https://t.co/BUz3NRL77J #Myeloma… https://t.co/jlU26eqUMI https://t.co/uzmrCMo348
-
-
Mashup Score: 4Antigen escape as a mechanism of resistance to T-cell-engaging therapies in multiple myeloma - 12 day(s) ago
Here, we summarize a presentation by Paola Neri on the mechanisms of antigen escape after T-cell-redirecting therapies, presented at the 5th Immune Effector Cell Therapies in Multiple Myeloma Workshop.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6What is the rationale for monitoring secondary malignancies after BCMA and CD19 CAR T-cell therapy? - 16 day(s) ago
The Multiple Myeloma Hub and Lymphoma Hub were pleased to speak to Anna Sureda, Catalan Institute of Oncology, Barcelona, ES. We asked, What is the rationale for monitoring secondary malignancies after BCMA and CD19 CAR T-cell therapy?
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 23Symposium | BCMA-directed bispecific antibodies - 17 day(s) ago
During the Multiple Myeloma Hub virtual symposium, Naresh Bumma, The Ohio State University, Columbus, US, delivered a presentation on BCMA-directed bispecific antibodies in MM.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 20
Here, we summarize a publication by Mohty et al. in the British Journal of Haematology on patient-reported outcomes following treatment with elranatamab in the phase II MagnetisMM-3 clinical trial.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5
Here, we summarize a subanalysis by Oriol et al. published in Clinical Lymphoma, Myeloma and Leukemia on the results of the OPTIMISMM trial by frailty status and bortezomib dose adjustment.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
Could modality and administration route of BCMA-directed immunotherapies impact incidence and rate of CRS in patients with relapsed/refractory #MultipleMyeloma? Read our article to learn the latest data! https://t.co/JmU6vhZta1 #mmsm #myeloma #CRS https://t.co/mKwdM4k1gD